Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial

Starting soon · Phase 4 · Has a placebo group

Conditions studied: Small Intestinal Bacterial Overgrowth Syndrome (SIBO), IBS

In brief

Small intestinal bacterial overgrowth (SIBO) is a common condition associated with gastrointestinal symptoms such as bloating, abdominal pain, diarrhea, and constipation, particularly in patients with irritable bowel syndrome. Antibiotic therapy with rifaximin is commonly used, but relapse rates remain high. This randomized, placebo-controlled clinical trial aims to evaluate whether supplementation with a multispecies probiotic containing Enterococcus faecium and Bacillus subtilis improves the effectiveness of rifaximin therapy in adult patients with SIBO. Participants will be randomly assigned to receive either rifaximin plus the probiotic or rifaximin plus placebo. Clinical assessments will include hydrogen breath testing and evaluation of gastrointestinal symptoms using standardized questionnaires at baseline and during follow-up visits. The study is being conducted at a single academic medical center in Poland and is sponsored by Państwowy Instytut Medyczny MSWiA. The probiotic and rifaximin are provided by Urgo. The results of this study may help determine whether probiotic supplementation can improve treatment outcomes and reduce recurrence of SIBO.

Key facts

Study ID

NCT07426705

Run by

Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji

People needed

100

Starts

2026-02-15

Expected to finish

2027-07-15

Last updated by the study team

2026-02-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years.
• Meets Rome IV criteria for irritable bowel syndrome.
• Written informed consent to participate in the study.

You may not qualify if…

• Lack of cooperation with investigators.
• Age >75 years.
• Need for modification of gastrointestinal treatment during the study.
• Use of antibiotics within 4 weeks before screening.
• Use of probiotics within 7 days before screening.
• Endoscopic examination within 6 weeks before screening or during the study without investigator approval.
• History of abdominal surgery.
• Crohn's disease, ulcerative colitis, microscopic colitis, celiac disease, cystic fibrosis, chronic pancreatitis, liver cirrhosis, or end-stage renal disease.
• Low FODMAP diet within 4 weeks before screening.
• Pregnancy or breastfeeding.
• Lactulose intolerance.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.